BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34716195)

  • 1. DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.
    Venugopal K; Feng Y; Nowialis P; Xu H; Shabashvili DE; Berntsen CM; Kaur P; Krajcik KI; Taragjini C; Zaroogian Z; Casellas Román HL; Posada LM; Gunaratne C; Li J; Dupéré-Richer D; Bennett RL; Pondugula S; Riva A; Cogle CR; Opavsky R; Law BK; Bhaduri-McIntosh S; Kubicek S; Staber PB; Licht JD; Bird JE; Guryanova OA
    Clin Cancer Res; 2022 Feb; 28(4):756-769. PubMed ID: 34716195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
    Shabashvili DE; Feng Y; Kaur P; Venugopal K; Guryanova OA
    Exp Hematol; 2022 Jun; 110():20-27. PubMed ID: 35306047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.
    Yuan XQ; Chen P; Du YX; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Zeng WJ; Chen XP
    J Transl Med; 2019 Jul; 17(1):220. PubMed ID: 31291961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
    Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
    Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
    Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with
    Sidorova OA; Sayed S; Paszkowski-Rogacz M; Seifert M; Camgöz A; Roeder I; Bornhäuser M; Thiede C; Buchholz F
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269477
    [No Abstract]   [Full Text] [Related]  

  • 9. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
    Marcucci G; Metzeler KH; Schwind S; Becker H; Maharry K; Mrózek K; Radmacher MD; Kohlschmidt J; Nicolet D; Whitman SP; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2012 Mar; 30(7):742-50. PubMed ID: 22291079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.
    Gamlen HA; Romer-Seibert JS; Lawler ME; Versace AM; Goetz ML; Feng Y; Guryanova OA; Palmisiano N; Meyer SE
    Clin Cancer Res; 2022 Oct; 28(20):4574-4586. PubMed ID: 35943291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia with DNMT3A mutations.
    Li Y; Zhu B
    Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.
    Que Y; Li H; Lin L; Zhu X; Xiao M; Wang Y; Zhu L; Li D
    Front Immunol; 2021; 12():653030. PubMed ID: 34093541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A-Mutant Leukemia Cells Primed to "Fork It Over" under DNA Damage.
    Viny AD
    Clin Cancer Res; 2022 Feb; 28(4):573-575. PubMed ID: 34880109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of three novel DNMT3A mutations with compromising methylation capacity in human acute myeloid leukaemia.
    Ali AM; Salih GF
    Mol Biol Rep; 2022 Dec; 49(12):11685-11693. PubMed ID: 36175738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
    Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
    Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
    Dong Y; Zhao X; Feng X; Zhou Y; Yan X; Zhang Y; Bu J; Zhan D; Hayashi Y; Zhang Y; Xu Z; Huang R; Wang J; Zhao T; Xiao Z; Ju Z; Andreassen PR; Wang QF; Chen W; Huang G
    Leukemia; 2019 Nov; 33(11):2585-2598. PubMed ID: 30967619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.